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Introduction
Fungal infections are a major clinical health prob-
lem that affects more than 300 million people 
annually.1 Candida glabrata is a commensal yeast 
living in human mucosal surfaces (e.g. mouth, 
esophagus, intestine) but can easily turn into a 
pathogen, especially in immunocompromised 
individuals, instigating a high rate of morbidity 
and mortality.2–5 In clinical practice C. glabrata is 
the second most prevalent pathogen in humans in 
the United States, and the third in Europe, after 
Candida albicans and Candida parapsilosis.3,6 This 
species is highly resistant to antifungal agents7–9 
and has high capacity to produce biofilms,10–12 
which are extremely refractory to antimicrobial 
therapy, thus being very difficult to treat with the 
traditional antifungal therapies.10,13–20 Formation 
of bioflims by Candida species in mouth and/or 
esophageal mucosae is very common, with C. 
glabrata21–23 being a very important contributor 
to human oral disease due to a high level of anti-
fungal resistance.24–26 Biofilms are biological 
communities with an extraordinary degree of 
organization, in which microorganisms form 
structured, coordinated, and functional commu-
nities, embedded in an extracellular matrix.24–26 
These structures are known to induce high rates 
of morbidity and mortality, especially in immuno-
compromised patients,27–29 creating a dangerous 
prospect of ineffective therapies against infectious 
diseases caused by Candida. The National 
Institutes of Health signposts that biofilms are 
directly or indirectly responsible for over 80% of 
all microbial infections.30–32 Therefore, there is an 
urgent need to overcome the numbers related to 
biofilm-associated C. glabrata infections and to 
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understand the mechanisms behind the response 
of C. glabrata biofilms infections to antifungal 
treatment.
Mucositis (or oropharyngeal candidiasis) is a fre-
quent infection among immunocompromised 
patients,33,34 which is characterized by the pres-
ence of creamy, white plaques on the tongue and 
buccal mucosa that generally leave a raw, painful, 
and ulcerated surface when scraped. Although 
not being a severe infection normally, it can be 
uncomfortable and detrimental to the patient’s 
nutritional status thanks to the diminished food 
and liquid intake. The latest 2016’s guidelines 
recommend the treatment general mucositis 
infections with oral fluconazole.35 However, the 
number of effective antifungal drugs is limited, and 
resistance to frequently used agents is emerging.24 
Specifically, the resistance of C. glabrata to the 
azole class of drugs has been well described.25
Candida biofilm matrix is mainly composed of 
exopolysaccharides, the most predominant being 
β-glucans. These D-glucose-based polysaccha-
rides are present in different types of glycosidic 
bonds,26,36–38 consisting of a repeating structure 
with the β-D-glucose units linked together in lin-
ear chains by β-bonds, forming homoglucans, 
which can extend either from carbon 1 of one sac-
charide ring to carbon 3 of the next (β1 → 3) or 
from carbon 1 to carbon 6 (β1 → 6). This net of 
polymers hampers the diffusion of azoles through 
the biofilms and, thus prevents the drug from 
reaching cells inside them.39–41
Ascorbic acid, also designated as vitamin C, 
has being used concomitantly in antibiotherapy 
for its capacity to boost the immune system and 
role as a helper in the treatment of several infec-
tions, for several years.42 AA’s concentration in 
phagocytes and lymphocytes is very high com-
pared with the level in plasma, indicating that AA 
may have functional roles in these immune sys-
tem cells, for example, increasing the functioning 
of phagocytes, the proliferation of T-lymphocytes 
and the production of interferon, and decreasing 
the replication of viruses.43 Furthermore, its 
metabolism is affected by various infections (e.g. 
common cold, pneumonia resultant from many 
microorganisms, scurvy or Helicobacter pylori 
infections), proposing that there might be 
treatment benefits in the association of this com-
pound to the regular pharmacotherapy.44–47 
Furthermore, AA’s metabolism also has the 
capacity to induce formation of hydroxyl radicals 
(OH•), which are reactive oxygen species that 
may oxidize biomolecules such as proteins, DNA, 
and other biopolymers (e.g. β-glucans).
So, the goal of this study was to check the in vitro 
efficacy, already demonstrated on the use of AA 
with antibiotics, will also be the same with an 
antifungal agent. Therefore, AA will be used con-
comitantly with Flu to treat C. glabrata biofilm 
oral infections.
Materials and methods
Organisms and growth conditions
C. glabrata ATCC2001 (reference strain from the 
American Type Culture Collection) was used 
in the course of this study. For each experiment, 
C. glabrata ATCC2001 was subcultured on 
Sabouraud dextrose agar (SDA; Merck, 
Darmstadt, Germany) for 24 h at 37°C. Cells 
were then inoculated in Sabouraud dextrose 
broth (Merck, Darmstadt, Germany) and incu-
bated for 18 h at 37°C under agitation at 120 rpm. 
After incubation, cells were harvested by centrifu-
gation at 3000 g for 10 min at 4°C and washed 
twice with phosphate buffered saline (PBS, 
pH = 7.5). Pellets were then suspended in RPMI 
1640 (Sigma-Aldrich, Roswell Park) and the cel-
lular density was adjusted to 1 × 105 cells/ml using 
a Neubauer counting chamber.48
Flu and AA
Flu was kindly provided by Pfizer®. AA was pur-
chased from Sigma-Aldrich (Roswell Park). 
Aliquots of 5000 mg/l were prepared using dime-
thyl-sulfoxide (DMSO), and the final concentra-
tions used (30 and 40 mg/l for Flu and 200 and 
300 mg/l for AA) were prepared with RPMI 1640. 
Controls were performed with DMSO in order to 
assure that the concentration used was not toxic 
(concentrations below 1% (v/v) DMSO).
Flu and/or AA effect on C. glabrata biofilm
Biofilm formation. Cell suspension was prepared 
and washed as described above and resuspended in 
RPMI 1640. Then, standardized cell suspensions 
(200 µl) were placed into selected wells of 96-well 
polystyrene microtiter plates (Orange Scientific, 
Braine-l’Alleud, Belgium). As a negative control, 
RPMI 1640 was used without cells and antifungal 
agent. As positive control, only cell suspensions 
were tested without antifungal agent. After 24 h, 
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100 µl of RPMI 1640 was removed and an equal 
volume of fresh RPMI 1640 plus the antifungal 
agent (2× concentrated) or the combination of flu 
and AA was used. The plates were incubated at 
37°C for an additional 24 h period, a total of 48 h 
at 120 rpm. In addition, in order to assess the effect 
of glucose in the medium, the assay was performed 
in the same conditions explained above using 
RPMI supplemented with 2% of glucose.
Biofilm cultivable cells and biomass determina-
tion. The number of cultivable cells in the bioflim 
was determined by the enumeration of colony 
forming units (CFUs). For that, after the period 
of biofilm formation, all medium was aspired and 
the biofilms were washed once with 200 µl of PBS 
to remove non-adherent cells. After biofilms were 
scraped from the wells and the suspensions were 
vigorously vortexed for 2 min to disaggregate cells 
from the matrix. Serial decimal dilutions in PBS 
were plated on SDA and incubated for 24 h at 
37°C. The results were presented as total of CFUs 
per unit area (Log10 CFUs/cm2). Total biofilm 
biomass was quantified by crystal violet (CV) 
staining. After the biofilm formation, the medium 
was aspirated and non-adherent cells removed by 
washing the biofilms with sterile ultra-pure water. 
Biofilms were then fixed with 200 µl methanol, 
which was removed after 15 min of contact. The 
microtiter plates were allowed to dry at room 
temperature, and 200 µl of CV (1% v/v) added to 
each well and incubated for 5 min. The wells were 
then gently washed twice with sterile, ultra-pure 
water and 200 µl of acetic acid (33% v/v) was 
added to release and dissolve the stain. The absor-
bance of the obtained solution was read in tripli-
cate in a microtiter plate reader (Bio-Tek Synergy 
HT, Izasa, Lisbon, Portugal) at 570 nm. The 
results were presented as percentage of biomass.48 
All the assays were performed in triplicate and on 
three separate occasions.
Statistical analysis
Results were compared using one-way analysis of 
variance (ANOVA), Dunnett’s and Bonferroni’s 
multiple comparisons test, using GraphPad Prism 
5 software. All tests were performed with a confi-
dence level of 95%.
Results
The present study aimed to evaluate an alterna-
tive treatment for oral mucositis related to C. 
glabrata biofilms using an combination of Flu and 
AA, similar to what has been used for treatment 
of bacterial infections for years. To determine the 
influence of AA in the fungistatic activity of Flu, 
C. glabrata ATCC2001 biofilms were grown for 
24 h and then different concentrations of these 
agents were added and allowed to incubate for an 
additional period of 24 h. The working concentra-
tions, for both Flu and AA, were chosen accord-
ing to their use in clinical practice, since the goal 
was to overtake the biofilm resistance of C. 
glabrata, using Flu in the same doses, but with 
another compound as an adjuvant.
Figure 1 shows the percentage of biomass of C. 
glabrata ATCC2001 when exposed to different 
concentrations of AA combined with Flu, in a 
pre-formed 24-h-biofilm. Controls were per-
formed with the two agents alone. After 24 h of 
exposure, AA alone had no effect on the reduc-
tion of the biofilm biomass, compared with the 
lower dose of Flu. Furthermore, AA showed to be 
an enhancer of C. glabrata’s biomass (Figure 1). 
On the other hand, combining 30 mg/l of Flu with 
both concentrations of AA, the biomass presented 
a statistically significant reduction (p < 0.001), 
compared with the use of Flu alone, however, in 
a very low percentage: 10–20%. Moreover, when 
the Flu concentration was higher, this effect was 
not noticed. An increase in biofilm biomass was 
also observed in the presence of the higher con-
centration of AA when used with the 40 mg/l of 
Figure 1. Percentage of biomass detected using 
CV staining with Flu and Flu + AA in biofilms of 
Candida glabrata ATCC2001 (*p < 0.05; **p < 0.01; 
***p < 0.001). The control is considered to have 100% 
of biomass production.
AA, ascorbic acid; CV, crystal violet.
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Flu. In order to explain the results obtained 
regarding the lack in the drug activity of Flu, via-
bility of cells after treatment was also assessed 
(Table 1) for the drugs alone. It was verified that 
using AA, the viable cells increased (around 10% 
and 15% for 200 and 300 mg/l of AA, respec-
tively), when compared with the controls. Flu was 
unable to eradicate 50% of C. glabrata viable cells 
even at higher concentrations (Table 1). In fact, 
when the highest concentration of Flu (40 mg/l) 
was used, it was only possible to reach a reduction 
of 7.0% in terms of biofilm cell viability (Table 1). 
With 30 mg/l, the values were rather superior 
(9.1%), but with no biomass reduction (Figure 
1), thus not therapeutically interesting.
To verify if the possibility of whether the increased 
glucose concentration resulting from the 
β-glucans hydrolysis was contributing to the 
increase in the C. glabrata population, another 
assay was performed. The RPMI was supple-
mented with 2% of glucose for three selected 
conditions: 200 mg/l of AA, 30 mg/l of Flu, and 
30 mg/l of Flu + 200 mg/l of AA (Figure 2). With 
extra glucose in the medium, the growth in 
control was 10% more than the control without 
glucose. Also, significant results were obtained 
when comparing the use of 200 mg/l of AA with 
30 and 40 mg/l of Flu alone (p < 0.01 and 
p < 0.001, respectively). No significant differ-
ences were obtained when comparisons with the 
drug combinations were made (Figure 2).
Lastly, concerning the drug combination (30 mg/l 
Flu + 200 mg/l AA), results show that the pres-
ence of glucose (Figure 2) in the medium was 
clearly harmful, since there was no variation in 
CFU count (thus, no cell death) comparing with 
the respective control. Additionally, when com-
paring this result with the control without glu-
cose, there was an increase in cell population 
(Figure 2).
Discussion
Mucositis associated to erythematous ulcerations 
in the oral cavity causes pain, xerostomia, dys-
phagia, and lastly septicaemia.49 It disturbs func-
tions such as drinking, eating, speaking, dental 
and other mouth care practices, and it affects not 
only nutrition and quality but also can be life 
threatening.23,49
Despite the recognized resistance profile of 
Candida biofilm cells to antifungal agents,15,17,18 
mucositis still has good outcomes with the use of 
azoles, particularly Flu.23,33,35,50 The knowledge 
that the therapeutic response of C. glabrata oral 
biofilms to Flu is lower than the other Candida 
species (e.g. C. parapsilosis or Candida guillermon-
dii)24–26 is the main reason for the development of 
the present study, in which clinical doses of Flu 
are associated with AA.
It was verified (Figure 1) that AA alone had no 
effect on the reduction of the biofilm biomass, 
compared with 30 mg/l of Flu, and it showed an 
increase in the growth of C. glabrata’s biomass. 
Generally, no significant differences were obtained 
when comparisons with the drug combinations 
were made. With the aim of explaining these 
results, cell viability after treatment with the drugs 
alone was also assessed (Table 1). It was then pos-
sible to observe, contrarily to what was expected, 
an increase in the cell viability, showing a possi-
ble degradation and consumption of β-glucans. 
Table 1. CFUs count (Log10 CFUs/cm2) when 
using AA and Flu alone in biofilms of Candida 





Control 6.22 ± 0.02 –
AA 200 mg/l 6.83 ± 0.25 −9.8
AA 300 mg/l 7.22 ± 0.05 −16.08
Flu 30 mg/l 5.65 ± 0.11 9.1
Flu 40 mg/l 5.78 ± 0.48 7.07
AA, ascorbic acid; CFU, colony forming units.
Figure 2. Cell production with Flu and Flu + AA in 
biofilms of Candida glabrata ATCC2001 (*p < 0.05; 
***p < 0.001), by CFUs count (Log10 CFUs/cm2).
AA, ascorbic acid; CFU, colony forming unit.
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In fact, other researchers described that during the 
degradation of AA, the hydrolysis into glucose 
monomers occurred.51,52 Xu et  al.,53 have also 
showed a similar situation. The authors tested a 
considered antifungal drug compound, β-1,3 glu-
canase, in a C. albicans strain, but instead of hav-
ing a reduced yeast count, there was a proliferation 
in C. albicans, which can be explained by the same 
reasons mentioned above. Similar to the goal of 
this work, Al-Fattani and Douglas54 tested various 
enzymes to degrade biofilms and noted that they 
were also easily detached from biofilms, but as 
specific hydrolase enzymes, they released many 
glucose monomers. Despite this fact and since the 
authors used amphotericin B as the antifungal 
agent, the results for the CFU count were 
favorable.
The chemical events underlying this process were 
explained through the β-glucan degradation 
pathways.55–58 Thereby, there are, mainly, two 
paths: (1) the oxidative cleavage of β-glucan is 
initiated by the removal of a hydrogen atom from 
the anomeric carbon (C1) of the polysaccharide 
inducing the formation of an alkyl radical, and 
there are two possible courses for the cleavage of 
the glycosidic bond with the generation of a lac-
tone in C1. The glycosidic bond may fragment 
due to delocalization of the unpaired electron, 
leading to the release of a β-glucan fragment with 
a lactone, and of a β-glucan fragment with an 
alkyl radical, which may react with O2 to form the 
corresponding peroxyl radical, which can further 
undergo transformations. Also, the glucan with 
an alkyl radical on the C1 can also suffer hydroly-
sis, which would point to the release of a non-
radical β-glucan fragment (glucose monomers) 
and a β-glucan fragment containing a radical at 
C1; (2) the formation of peroxyl radical following 
the alkyl radical in C1. The carbon-centered rad-
ical in C1 would react rapidly with O2 to give a 
peroxyl radical, which can further combine with 
another peroxyl radical and fragment via an 
alkoxyl radical (R–O•).46 The alkoxyl radical 
formed would undergo a β-fragmentation, liber-
ating a β-glucan fragment with a lactone in C1 
and a β-glucan fragment with an alkoxyl radical at 
C3. Other pathways can contribute to the scission 
of β-glucan, since the non-selective attack of •OH 
radicals most likely also generate radicals at other 
locations besides C1.44,59
In fact, a loss of viscosity in the biofilm was 
observed during the biofilm manipulation 
whenever AA was used. The biofilm was more 
flexible and easily breakable, which is related 
to the formation of hydroxyl radicals during 
β-glucan degradation.44,57,60,61 Actually, this 
glucose hydrolysis reaction is used as an alterna-
tive method to the DuBois et al.62 for carbohy-
drate quantification.63,64
In the concomitant use of Flu and AA (30 mg/l 
Flu + 200 mg/l AA), the addition of glucose to the 
RPMI was very unfavorable. No cell death was 
achieved (there was no variation in the CFU count), 
compared with the respective control. In fact, there 
was even a small increase in cell population (Figure 
2) because of the consumption of the free glucose 
derived from the hydrolysis of the β-glucans and/or 
the supplementation of the medium, which dis-
rupted the Flu fungistatic activity.
To conclude, Flu is a drug that is significant in 
the treatment of mucositis. Although with certain 
side effects, it is generally well tolerated, it has 
low toxicity, and the usual therapeutic regimen is 
very appealing to the patient. Unfortunately, once 
more, the final data presented indicate that this 
drug might not work for infections derived from 
C. glabrata biofilms, as previous work from our 
group have demonstrated. The matrix of Candida 
biofilms is a solid barrier to the diffusion of drugs 
into the cells. Thus, the use of a drug combina-
tion in which one drug would degrade this matrix 
and the other drug would be fungicidal or fungi-
static could be a good strategy and improve the 
therapeutic response in fungal infections. Flu has 
been shown to be recalcitrant in vitro due to the 
lack of drug penetration.41
AA leads to hydrolysis of β-glucan which forms 
glucose that is later used as carbon source by C. 
glabrata, enabling the cells to colonize and infect. 
Thus, their virulence was not annulled by Flu in 
this drug combination. Though this outcome 
might be possible in other Candida strains and/or 
species, this work has a clear limitation because of 
the use of a single strain and thus the results can-
not be directly generalized to all C. glabrata strains.
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